WO2007043629A1 - エフリンb2を用いる血管新生の抑制方法 - Google Patents
エフリンb2を用いる血管新生の抑制方法 Download PDFInfo
- Publication number
- WO2007043629A1 WO2007043629A1 PCT/JP2006/320423 JP2006320423W WO2007043629A1 WO 2007043629 A1 WO2007043629 A1 WO 2007043629A1 JP 2006320423 W JP2006320423 W JP 2006320423W WO 2007043629 A1 WO2007043629 A1 WO 2007043629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ephrin
- angiogenesis
- neovascularization
- diabetic
- endothelial cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Definitions
- the present invention relates to methods and compositions for inhibiting angiogenesis or angiogenesis, and more particularly to the use of ephrin B 2 in the methods and compositions.
- Angiogenesis is a prominent feature of various ocular pathological conditions such as age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity.
- the angiogenic cascade is caused by many mediators and chemokines.
- endothelial cell receptor tyrosine kinase RTK
- RTK endothelial cell receptor tyrosine kinase
- an angiogenic site force-in is generated that includes vascular endothelial growth factor (VEG 'F), an event that applies well to the concept of capillary development.
- angiopoietin ZT 1 e 2 system has been identified as a ligand-receptor system that mediates vascular assembly and maturation.
- the VEGFZVEGF receptor opiopoietin ZT i e 2 family also belongs to RTK.
- Eph receptor The Eph receptor, the ephrin receptor, consists of 8 Eph A receptors and 6 Eph B receptors, including the largest family of tyrosine kinase receptors.
- This E rho receptor receptor synkinase family represents a new class of RT K. This family is originally identified as a neuronal pathway pioneer, but its role in angiogenesis is unknown.
- E ph B receptors and ephrin B ligands have been identified as important regulators of vascular assembly that organize arteriovenous differentiation and border formation ( Non-patent documents 2, 3, 5).
- Eph B4 the initial marker of vesicles, is a marker of venous endothelial cells in vertebrate embryos (Non-patent Documents 1, 2, 4, 6) .
- endothelial cells in adults maintain their asymmetric arteriovenous expression pattern, which is responsible for the regulation of vascular homeostasis by the ephrin B / Eph B system, and pathological angiogenesis in adults It has been suggested that it has the possibility of controlling (Non-Patent Documents 3 and 5).
- Eph receptor antagonist eg, antibody
- an agonist stimulates angiogenesis
- Patent Document 1 It is therefore desirable to determine the mode of action of ephrin and to be able to use these molecules to manipulate the vasculature, particularly in pathological conditions.
- Diabetic retinopathy is a leading cause of blindness in people between the ages of 20 and 65 in the United States.
- the essential pathology of diabetic retinopathy is retinal microangiopathy and subsequent ischemia. It is well known that hypoxia in retinopathy leads to retinal neovascularization. However, in the newly formed vasculature due to retinal neovascularization, the blood flow is not perfused and the retina is in an ischemic state. Because these vessels are immature and leaky. In addition, these vessels often penetrate the vitreous chamber.
- the ideal treatment for diabetic retinopathy is to obtain a mature vessel that can inhibit the development of blood vessels with this misdirected orientation, and perfuse the ischemic retina and rescue from hypoxia It is.
- Age-related macular degeneration is the leading cause of blindness in adults in Europe and the United States, and one of the three major causes in Japan. It is the essence of the pathological condition that the neovascularization enters the macula from the choroid, which leads to social blindness due to bleeding from the abnormal neovascularization and retinal detachment. Therefore, suppressing the occurrence of abnormal new blood vessels is an essential treatment for maintaining visual function. It is known that the growth of new blood vessels is suppressed by the pigment epithelium covering the new blood vessels, but the mechanism of action is not yet well known.
- Patent Document 1 US Patent Application Publication No. 2004/0 1 36 983
- Non-Patent Document 1 Adams, RH et al. (2001) Cell, 104 ⁇ , 1, 57-69
- Non-Patent Document 2 Adams, RH et al. (1999) Genes Dev., 13 ⁇ , No. 3, pp. 295-306
- Non-Patent Document 3 Gale, N.W. et al., (2001) Dev. Biol., 230 ⁇ , No.2, pp. 151-160
- Non-Patent Document 4 Gerety, S.S. et al. (1999) ol. Cell, 4 ⁇ , No. 3, pp. 403-414 '.
- Non-Patent Document 5 A Shm, D. et al. (2001) Dev. Biol., 230 ⁇ , No. 2, pp. 139-150,
- Non-Patent Document 6 Wang, H.U., et al. (1998) Cell, 93 ⁇ , No. 5, pp. 741-753 DISCLOSURE OF THE INVENTION Problems to be solved by the invention.
- An object of the present invention is to provide a method, a composition, and a preventive / therapeutic agent for suppressing angiogenesis or angiogenesis.
- An object of the present invention is to provide a method, a composition, and a prophylactic / therapeutic agent useful for treating a disease or disorder associated with angiogenesis or angiogenesis.
- the present invention provides a method for inhibiting DNA synthesis in arterial endothelial cells (or venous endothelial cells), which comprises contacting arterial endothelial cells (or venous endothelial cells) with an effective amount of ephrin B 2. including.
- the DNA synthesis is induced by vascular endothelial growth factor (VEGF), basic fibroblast growth factor (b FGF), or platelet derived growth factor (PDG F).
- VEGF vascular endothelial growth factor
- b FGF basic fibroblast growth factor
- PDG F platelet derived growth factor
- the present invention also provides p 44 p 42 in arterial endothelial cells (or venous endothelial cells).
- MAP kinase activation comprising arterial endothelial cells (Or venous endothelial cells) comprising contacting an effective amount of ephrin B2.
- the p44p4 2 MA P kinase activation is induced by VEGF, bFGF, or PDGF.
- the present invention also provides a method of inhibiting angiogenesis from arterial endothelial cells (or venous endothelium 'cells), which comprises an arterial endothelial cell (or venous endothelial cell) with an effective amount of ephrin B 2 And contacting with.
- the angiogenesis is induced by VEGF, bFGF, or PDGF. '
- the contacting step is performed by administering the ephrin B2 to a mammal having the arterial endothelial cells (or venous endothelial cells).
- the present invention also provides a method of inhibiting angiogenesis from the retina, the method comprising the step of administering to the individual an effective amount of ephrin B2.
- the individual is an individual who has or can have pathological angiogenesis or neovascularization outside the retina.
- the present invention also provides a method of treating a disease or disorder associated with angiogenesis or angiogenesis, the method comprising administering an effective amount of ephrin B2 to an individual in need of such treatment.
- the present invention also provides a composition for inhibiting DNA synthesis of arterial endothelial cells (or venous endothelial cells) comprising an effective amount of ephrin B2.
- the present invention also provides a composition for inhibiting p44Zp42 MAP kinase activation of arterial endothelial cells (or venous endothelial cells) comprising an effective amount of ephrin B2.
- the present invention also provides a composition for inhibiting angiogenesis from arterial endothelial cell (or venous endothelial cell) force comprising an effective amount of ephrin B2.
- the present invention also provides a composition for inhibiting angiogenesis from the retina comprising an effective amount of ephrin B2.
- the present invention also provides a pharmaceutical composition for the treatment of a disease or disorder associated with angiogenesis or angiogenesis, comprising an effective amount of ephrin B2.
- the present invention also provides a DNA synthesis inhibitor of arterial endothelial cells (or venous endothelial cells) comprising an effective amount of ephrin B2. '
- the present invention also provides an arterial endothelial cell (or venous endothelial cell) p 4 4 Z p 4 2 MA P kinase activation inhibitor comprising an effective amount of ephrin B 2.
- the present invention also provides an angiogenesis inhibitor from arterial endothelial cells (or venous endothelial cells) comprising an effective amount of ephrin B2.
- the present invention also provides a retinal neovascularization inhibitor comprising an effective amount of ephrin B2.
- the present invention also provides a therapeutic agent for a disease or disorder associated with angiogenesis or angiogenesis, comprising an effective amount of ephrin B2.
- the ephrin B 2 comprises a natural ephrin B 2 extracellular domain, but the cytoplasmic domain. And does not contain a transmembrane domain.
- the disease or disorder is age-related macular degeneration, ischemic retinopathy, intraocular neovascularization, cornea Angiogenesis, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retinal ischemia, diabetic retinal edema, diabetic retinopathy, cancer, chronic arthritis, umati, endometriosis, and alopecia Selected from the group consisting of
- the disease or disorder is age-related macular degeneration, ischemic retinopathy, intraocular neovascularization. Selected from the group consisting of: corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retinal ischemia, diabetic retinal edema, and diabetic retinopathy.
- the invention's effect According to the present invention, methods and compositions for inhibiting angiogenesis or angiogenesis are provided.
- the compositions and methods of the present invention can inhibit pathological angiogenesis or angiogenesis without reducing physiological blood flow.
- the compositions and methods of the present invention do not affect normal blood vessels and are therefore useful for the treatment of diseases or disorders associated with angiogenesis or angiogenesis.
- FIG. 1A is a graph showing the effect of thymidine incorporation by ephrin B 2 treatment and Ep hB4 treatment on HAo E C treated with VEGF, 'b FGF, or PDGF-BB. '
- FIG. 1B is a graph showing the effect of thymidine incorporation by ephrin B 2 treatment and E ph B 4 treatment in HUVEC treated with VEGF, bFGF, or PDGF_BB. ,
- Figure 1C shows the control with either control (untreated), s ephrin B 2 or s E ph B 4, or both s ephrin B 2 and s E ph B 4 7 is a photograph showing the morphology of endothelial cells stimulated with VEGF after 7 days.
- FIG. 2A is an electrophoretogram showing the effect of ephrin B 2 on ERK phosphorylation in HAo EC stimulated with VEGF or bFGF.
- FIG. 2B is an electrophoretogram showing the effect of ephrin B 2 on VEGF receptor 2 (KDR) autophosphorylation in VEGF-stimulated HAo EC.
- KDR VEGF receptor 2
- FIG. 3 is a graph showing the results of quantitative analysis of angiogenesis in the cornea of mice co-administered with bFGF and ephrin B2.
- Figure 4 is a fluorescence micrograph showing the morphology of a flat-mounted fluorescein-dextran perfused retina of a control (A) and sephrin-B treated model (B).
- Figure 5 shows the control model (OIR) and the sephrin B 2 treatment model (O It is a graph which shows the perfusion area
- Fig. 6 is a scanning electron micrograph showing the morphology of the retinal surface of a P17 neonatal mouse in the control model (OIR) (A) and the sephrin B2-treated model (011 + ephrin: 62) (B). . '
- FIG. 7 is a graph showing the effect of thymidine incorporation by mouse ephrin B 2 treatment and human ephrin B 2 treatment in HUVEC by bFGF treatment.
- FIG. 8 is a fluorescence photograph showing the state of the fundus oculi subjected to 10 ng / mL human ephrin B 2 treatment (A), PBS treatment (B), and 10 ng / mL mouse ephrin B 2 treatment (C). Best Mode for Carrying Out the Invention ''
- the ephrin B2 / EphB4 system plays an important role in angiogenesis and angiogenesis.
- the present invention is based on finding that it inhibits DNA synthesis of ephrin B2 force endothelial cells (EC) and p44 / p42 MAP kinase activation induced by both VE'GF and bFGF.
- Ephrin B2 also inhibits angiogenesis by EC.
- ephrin B 2 inhibits corneal angiogenesis induced by bFGF, according to the quantification of corneal micropocket corneal angiogenesis in mice. Therefore, angiogenesis-dependent diseases can be treated by targeting ephrin B2 / E ph B4 and its anti-angiogenic signaling pathway.
- ephrin B 2 has (1) substantial sequence similarity to natural ephrin B 2 or its extracellular domain, preferably natural human ephrin B 2. And (2) refers to a polypeptide having biological activity involving natural ephrin B2 or the extracellular domain.
- the term “Ephrin B 2” Natural ephrin B 2 (preferably natural human ephrin B 2) and its extracellular domain, and analogs and variants thereof having the biological activity of the natural ephrin B 2 or extracellular domain mentioned above included.
- the sequence of ephrin B 2 is known in the art, and those skilled in the art can fully recognize the sequences and positions of the extracellular domain, transmembrane domain, and cytoplasmic domain.
- Natural molecules like natural ephrin B 2 are naturally occurring molecules without artificial intervention.
- native ephrin B2 may also be an extracellular domain of ephrin B2 that exists without artificial intervention.
- Ephrin B 2 is ephrin B 2 containing both domains in extracellular cells.
- Full-length ephrin B2 can be naturally occurring or can be an analog or variant of natural ephrin B2.
- a polypeptide having “substantial sequence similarity” with a natural molecule is at least about 30% identical to the natural molecule at the amino acid level.
- the polypeptide is preferably at least about 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, and even at the natural molecule and amino acid level. Preferably at least about 98% identical, more preferably about 99% identical, even more preferably 100% identical.
- the term “percent identity” or “% identity” for an analog or variant with a natural molecule refers to the amino acid sequence of the natural molecule found in the analog or variant when the two sequences are aligned. A parcel. Percent homology can be determined by any method or algorithm established in the art, such as LALIGN, ClustalW, or BLAST.
- the polypeptide can bind to the receptor for native ephrin B 2, or it can induce EC DNA synthesis, extracellular signal-regulated kinase (ERK) phosphorylation in EC, EC angiogenesis, angiogenesis, or angiogenesis If it can be inhibited, it has “biological activity” involving natural ephrin B2. Inhibits EC DNA synthesis, ERK phosphorylation in EC, EC angiogenesis, angiogenesis, or angiogenesis The activity can be determined by any method known to those skilled in the art, for example, as described herein.
- ERK extracellular signal-regulated kinase
- an “effective amount” is an amount of a substance sufficient to achieve a desired purpose.
- an effective amount of ephrin B 2 to inhibit DNA synthesis is an amount sufficient to reduce the amount of DNA synthesis, depending on whether in vivo or in vitro.
- An effective amount of ephrin B 2 for treating a disease or disorder is an amount of ephrin B 2 sufficient to reduce or eliminate symptoms of the disease or disorder or to prevent or delay the disease or disorder.
- the effective amount of a given substance will vary depending on factors such as the nature of the substance, the route of administration, the size and species of the animal receiving the substance, and the purpose for which the substance is given. The effective amount in each case can be determined empirically by those skilled in the art according to methods established in the art.
- mice refers to any animal, preferably mammals other than humans or humans, more preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, Usi, horse, or primate, more preferably human.
- “Pathologic angiogenesis or neovascularization” can be the formation or neoplasia of blood vessels that are not physiologically normal. Since such blood vessels are immature and leaky, they can become blood vessels that cannot perfuse blood. Also, “pathological angiogenesis or angiogenesis” can be angiogenesis or neoplasia in a manner different from a physiologically normal state. For example, it also means that a new blood vessel is formed by receiving a stimulus such as inflammation.
- an “individual having or possibly having pathological angiogenesis or angiogenesis” refers to an individual who has already undergone angiogenesis or angiogenesis as described above, or such angiogenesis or An individual who can have a factor causing angiogenesis. The latter individuals are affected by a disease or disorder that may show signs of “pathological angiogenesis or neovascularization” but have not yet shown such signs, “pathological angiogenesis or It may be an individual who has been stimulated to cause “angiogenesis”. “Pathologic angioplasty or neovascularization” can occur “intraretinal” or “extraretinal”. “Outside the retina” means outside the tissue of the retina.
- Such angiogenesis or neovascularization includes, for example, the formation or neovascularization of blood vessels from the retina through the inner limiting membrane into the vitreous and the formation or neovascularization of blood vessels from the retina to the choroid.
- disease or angiogenesis-related disease or disorder results in the “pathological angiogenesis or angiogenesis” described above or to an individual due to “pathological angiogenesis or angiogenesis”.
- diseases or disorders include age-related macular degeneration 'f * disease, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retina Blood, diabetic retinal edema, diabetic retinopathy, cancer, rheumatoid arthritis, endometriosis, and alopecia.
- Treatment of a disease or disorder refers to reducing or completely eliminating the symptoms of the disease or disorder (also referred to as “treatment”), or preventing or delaying the onset of the disease or disorder.
- in need of treatment means that the individual will benefit from treatment (eg, for humans, doctors, nurses, clinical nurses, etc .; animals; non-human mammals). (Including animals) refers to decisions made by veterinarians. This determination is based on a variety of factors that are within the domain of the treatment service's opinion, but that the individual is currently ill as a result of a condition that can be treated with any composition. Or the recognition that it may become ill in the future.
- composition comprises at least one active ingredient and the cell, tissue, organ or animal of the subject to which the composition is applied or administered (preferably a mammal, more preferably a mouse, a rat, Substances intended to exert the effect of the active ingredient in other rodents, rabbits, dogs, cats, pigs, rabbits, horses, or primates, more preferably humans)
- a mammal more preferably a mouse, a rat
- a combination of A person skilled in the art will determine whether the active ingredient has the desired effective results based on the needs of the person skilled in the art. Understand and recognize the appropriate technology to determine.
- a “pharmaceutical composition” comprises at least one active ingredient, and is an animal, preferably a mammal, more preferably a mouse, a rat, other rodents, a rabbit, a dog, a cat, It refers to a combination of substances intended to exert the pharmaceutical effect of the active ingredient in pigs, tusks, horses, or primates, and more preferably humans.
- an animal preferably a mammal, more preferably a mouse, a rat, other rodents, a rabbit, a dog, a cat
- It refers to a combination of substances intended to exert the pharmaceutical effect of the active ingredient in pigs, tusks, horses, or primates, and more preferably humans.
- One skilled in the art understands and recognizes techniques suitable for determining whether an active ingredient has the desired effective results based on the needs of the artisan.
- inhibitor inhibitor
- inhibitor and “preventive / therapeutic agent” are those in which at least one active ingredient is prepared in a form suitable for application or administration to exert the effect of the active ingredient Say.
- these are the cells, tissues, organs or animals of the subject to which this composition is applied or administered (preferably mammals, more preferably mice, rats, other rodents, rabbits, dogs, cats,
- the effect of the active ingredient can be exerted in pigs, urchins, horses, or primates, and more preferably humans. '
- Endothelial cells can be induced to proliferate in response to growth factors such as VEGF, bFGF, or PDGF-BB (? 00: 6 subunit dimer).
- VEGF vascular endothelial growth factor
- bFGF vascular endothelial growth factor
- PDGF-BB PDGF-BB
- ephrin B2 inhibits DNA synthesis induced by all stimulation of VEGF, bFGF, or PDGF-BB.
- the increase in DNA synthesis induced by 10 ng / mL VEGF, b FGF, or PDGF-BB was 4 by 200 ng / mL ephrin B 2 respectively. ⁇ %, 30%, and 90% inhibited.
- ephrin B 2 human umbilical vein endothelial cells (HUVEC) (see Figure 1B). Inhibition of DNA synthesis by ephrin B 2 is not caused by apoptosis. Thus, ephrin B2 can inhibit EC DNA synthesis induced by a variety of stimuli, including VEGF, bFGF, and PDGF.
- the receptor for Ephrin B 2 (E p hB4) is a marker for venous endothelial cells, but DNA synthesis is not related to venous endothelial cells, although this receptor is not known to be present in arterial endothelial cells. It is inhibited in both arterial endothelial cells.
- VEGF-induced angiogenesis is not affected by E p hB 4 treatment.
- Ephrin B 2 inhibits the growth factor-induced mitotic response. This is because ephrin B 2 suppresses ERK (p 42/44) phosphorylation induced by both VEGF and b FGF in both arterial and venous endothelial cells. However, ephrin B 2 does not inhibit VEGF receptor 2 autoligation, which does not interfere with signal transduction between VEGF and VEGF receptor 2, as is the mechanism for inhibiting VE GF function. Show. Thus, ephrin B 2 can be used to inhibit V EG F or b F GF induced ER K phosphorylation in inner cells, either arteries or veins.
- b FGF is a powerful angiogenic factor.
- Ephrin B2 can inhibit EC cell proliferation induced by this bFGF.
- Administration of ephrin B 2 significantly blocks angiogenesis induced by bFGF.
- E phB4 administration does not show significant effects. (Eflin B 2 effect in an in vivo model)
- Corneal micropocket assembly is a representative in vivo model of angiogenesis.
- administration of ephrin B2 can significantly block angiogenesis induced by bFGF.
- EphB 4 administration does not show any effect.
- the oxygen-induced retinopathy (OIR) model is an animal model of diabetic retinopathy.
- ephrin B 2 is responsible for pathologic angiogenesis or out of the retina. It can inhibit vascular growth and enhance vascular network formation and vascular maturation in the membrane.
- the laser-induced choroidal neovascularization (CNV) model is positioned as an experimental disease model for age-related macular degeneration (AMD).
- Ephrin B 2 can suppress this C N V. '
- Ephrin B 2 suppresses the formation of pathological new blood vessels (eg, choroidal neovascularization, transendothelial neovascularization) going outside the retina without suppressing physiological blood flow in the retina. obtain. Therefore, ephrin B2 can be used to suppress pathological angiogenesis or angiogenesis without suppressing physiological blood flow.
- pathological new blood vessels eg, choroidal neovascularization, transendothelial neovascularization
- ephrin B 2 is age-related macular degeneration, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retinal ischemia, diabetic retinal edema Useful in the treatment of diabetic retinopathy, cancer, rheumatoid arthritis, endometriosis, and alopecia, and other diseases or disorders associated with angiogenesis or angiogenesis.
- ephrin B 2 is useful for the treatment of diseases or disorders associated with angiogenesis or angiogenesis in the eye.
- Ephrin B 2 is primarily responsible for retinal physiological blood flow, usually caused by treatment with currently used photodynamic therapy (PDT) and various anti-angiogenic agents (eg, anti-VEGF agents). Does not cause damage.
- PDT photodynamic therapy
- anti-VEGF agents eg, anti-VEGF agents
- ephrin B 2 can be used to treat wet and early dry AMD, for example, by inhibiting pathological choroidal neovascularization without damaging the retinal physiological blood flow.
- diabetic retinopathy can be treated by inhibiting pathological transmembrane endovascularization without damaging the retina's physiological blood flow.
- Ephrin B 2 useful in the present invention can be any ephrin B 2 including analogs and variants and has the required activity.
- Ephrin B 2 is an effect of the present invention.
- the structure is not limited as long as the " ⁇ " is displayed.
- Ephrin ⁇ 2 includes the extracellular domain, but may not include the cytoplasmic domain and the cell membrane domain, or may be the full length. Even a shorter fragment.
- the ephrin-2 used in the present invention may be one obtained by isolating and purifying a protein present in nature, or one produced from a microorganism by genetic recombination.
- a protein present in nature or one produced from a microorganism by genetic recombination.
- US Pat. No. 6,303,769 or Mol Immunol. 1995 Nov; 32 (16) '1197-205 A full-length protein, a protein containing an extracellular domain, and the like can be prepared using conventional techniques with reference to the sequence of ⁇ N B 2 cDNA.
- a person skilled in the art can also preferably modify natural ephrin B 2 by using techniques commonly used by those skilled in the art.
- Ephrin B 2 may be any commercially available drug or reagent.
- ephrin B2 when used in a pharmaceutical composition, it is more preferable that it is purified to a purity usually used for medical purposes.
- it can be modified into any form suitable for administration to an individual by fusing to the Fc domain of an immunoglobulin (preferably, the Fc domain of human IgG) in consideration of immunological characteristics.
- an immunoglobulin preferably, the Fc domain of human IgG
- a protein in which soluble ephrin B 2 usually containing an extracellular domain but not containing a cytoplasmic domain or a transmembrane domain
- a composition comprising ephrin B 2 can be used to administer the composition to an individual (eg, a subject animal) or a specimen (eg, a cell (eg, an endothelial cell, particularly an endothelial cell of an artery or vein), tissue, or It can be in various forms suitable for application to organs. Methods for preparing such forms are well known in the art. That is, the present invention also provides a formulation suitable for a predetermined use of ephrin B2.
- Formulations suitable for a given application include, but are not limited to, “inhibitors to inhibit DNA synthesis in arterial endothelial cells (or venous endothelial cells)”, “arterial endothelial cells (or “Inhibitors” that inhibit activation of p'4 4 Z p 4 2 MA P kinase in intravascular cells) "Inhibitors that inhibit angiogenesis from arterial endothelial cells (or venous endothelial cells)” , “Inhibitors for inhibiting angiogenesis from the retina” and the like.
- Such a formulation containing ephrin B 2 may contain other ingredients other than ephrin B 2 as long as they do not interfere with the action of ephrin B 2 and do not adversely affect the individual or specimen.
- the pharmaceutical composition comprising ephrin B2 can be in various forms of formulations suitable for administration to an individual. Methods for preparing such forms are well known in the art. That is, the present invention also provides a formulation suitable for a predetermined use of ephrin B2.
- the treatment suitable for a given application is not particularly limited, but “an inhibitor for inhibiting DNA synthesis in arterial endothelial cells (or venous endothelial cells)”, “arterial endothelial cells (or venous endothelial cells) Inhibitors to Inhibit P4 4 ZP 4 2 MA P Kinase Activation "," Inhibitors to Inhibit Angiogenesis from Arterial Endothelial Cells (or Venous Endothelial Cells) ",” Vessels from Retina " Inhibitors for inhibiting neoplasia ”,“ preventive / therapeutic agents for the treatment of diseases or disorders associated with angiogenesis or angiogenesis ”and the like.
- a preferred embodiment of the present invention relates to arterial endothelial cells.
- the present invention also includes ephrin B2, age-related macular degeneration, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retinal ischemia
- a pharmaceutical composition for the treatment of a disease or disorder selected from the group consisting of: diabetic retinal edema, diabetic retinopathy, cancer, rheumatoid arthritis, endometriosis, and alopecia Provide the agent.
- Ephrin B2 may treat or prevent at least one of the above diseases or disorders.
- a composition comprising B2 / b is an effective amount of ephrin B2 and a pharmaceutically acceptable carrier
- This composition may contain other pharmaceutically acceptable ingredients (including angiogenesis inhibitors other than ephrin B2) as long as they do not interfere with the action of ephrin B2.
- a pharmaceutical composition or a prophylactic / therapeutic agent mainly containing ephrin B 2 is also provided.
- Ephrin B2 can be administered systemically, eg, orally or by intramuscular or intravenous injection, mixed with a pharmaceutically acceptable carrier adapted to the route of administration.
- a pharmaceutically acceptable carrier adapted to the route of administration.
- physiologically acceptable carriers can be used to administer ephrin B 2 and its formulations are known to those skilled in the art, for example, Remington's Pharmaceutical Sciences (No. 18fe), A. Gennarofe Mack Publishing, ompany, Eastern, PA, and Pollock et al.
- Ephrin B 2 is preferably administered parenterally (eg, intramuscularly, intraperitoneally, 'intravenously, intraocularly, intravitreally, or subcutaneously, or by implantation).
- parenteral administration can be in the form of sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
- various aqueous carriers such as water, buffered water, and physiological saline can be used.
- suitable vehicles include polypropylene glycol, polyethylene glycol, vegetable oils, gelatin, hardened naphthalenes, and injectable organic esters such as ethyl oleate.
- Such formulations may also contain preservatives, wetting agents, buffering agents, emulsifying agents, and auxiliary substances such as Z or dispersing agents.
- auxiliary substances such as Z or dispersing agents.
- Biocompatible, biodegradable lactide polymers, lactide glycoside copolymers, or polyoxyethylene monopolyoxypropylene copolymers can be used to control the release of the active ingredient.
- ephrin B 2 can be administered by oral ingestion.
- Formulations intended for oral use can be prepared in solid or liquid form according to any method known in the art.
- the composition can optionally include sweetening, flavoring, coloring, flavoring, and preservatives to provide more palatable preparations.
- Solid dosage form formulations for oral administration include capsules, tablets, pills, powders, and granules. In general, these formulations contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients.
- Binders, buffering agents, and / or lubricants “ ⁇ ” may also be used.
- Tablets and pills can additionally be prepared with enteric coatings.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and soft gelatin capsules. -These forms of formulations contain inert diluents commonly used in the art such as water or oil media, and also contain adjuvants such as wetting agents, emulsifying agents, suspending agents and the like. obtain.
- Ephrin B2 can also be administered topically, for example, by means of a patch, by direct application to the eye, or by iontophoresis.
- Ephrin B2 can be provided as a sustained release formulation, for example, as described in US Pat. Nos. 5,672,659 and 5,595,760.
- immediate or sustained release compositions depends on the nature of the disorder being treated. If the disorder consists of an acute or hyperacute disorder, treatment in immediate release form is preferred over sustained release formulations. Alternatively, sustained release formulations may be appropriate for prevention or long-term treatment.
- Ephrin B2 can also be delivered using an implant.
- implants can be biodegradable and Z or biocompatible implants, or can be non-biodegradable implants.
- the implant can be permeable or impermeable to the active ingredient.
- the ocular implant can be inserted into an chamber, such as the anterior or posterior chamber, or it can be implanted into the sclera, the choroidal space, or the avascular region of the vitreous outer surface. Preferred embodiment In such a manner, the ocular implant can be placed in an avascular region such as the supremacy, thus allowing transscleral diffusion of the drug to the desired site of treatment, eg, the intraocular lumen and the macular of the eye. Furthermore, the site of transscleral diffusion is preferably near the macula.
- implants for delivery of ephrin B 2 include: US Pat. Nos. 3,416,530; 3,82 8,777; 4,014,335; 4,300,557; 4,327,725; 4 , 853, 224; 4, 946, 450; 4, 997, 652; 5, 247, 647, 5, 164, 188; 5, 178, 635, 5, 300, 114; 5, 322, 691; 5, 403 , 901; 5, 443, 5 05; 5, 466, 466; 5, 476, 511; 5, 516, 522; — 5, 632, 984; 5, 679, 666; 5, 710, 165; 5, 7 5, 743, 274; 5, 766, 242; 5, 766, 619; 5, 770, 592; 5, 773, 019; 5, 824, 07 2; 5, 824, 073; 5, 830 , 173; 5, 836, 935; 5, 869, 079; 5, 902, 598; 5, 904, 144, 5, 91 6, 5
- ephrin B 2 should be administered in an amount sufficient to reduce or eliminate signs of disease.
- Dosage levels on the order of about 1 g / kg to 100 mg / kg body weight per dose are generally useful for the treatment of angiogenic disorders.
- it is preferably administered so that the intraocular concentration is from about I ng / mL to about lOOng / mL.
- the dose can be administered as a single dose or can be divided into multiple doses. In general, longer dosing periods of several months or more may be required, but the desired dosage should be administered over an extended period of time, usually at least a few weeks.
- the exact individual dosage can be adjusted depending on, for example, a variety of factors: administration time; route of administration; nature of the formulation; The specific disorder being treated; severity of the disorder; and the age, weight, health status, and gender of the patient.
- administration time for example, a variety of factors: administration time; route of administration; nature of the formulation; The specific disorder being treated; severity of the disorder; and the age, weight, health status, and gender of the patient.
- the wide variation in dosage required should be predicted considering the different effectiveness of the various routes of administration. For example, oral administration is generally expected to require higher dosage levels than administration by intravenous or intravitreal injection.
- These dosage level variations can be adjusted using standard empirical routines for optimization well known in the art.
- the exact therapeutically effective dose level and pattern is preferably determined by the attending physician in view of the above factors.
- ephrin B 2 can be administered prophylactically to prevent or delay the onset of these disorders.
- ephrin B2 is administered to individuals who are prone to or at risk for certain angiogenic disorders. Also, the exact amount administered will depend on various factors such as the individual's health, weight, etc.
- ⁇ g microphone mouth gram
- DMEM Dulbecco's modified medium
- I TS Insulin 1 Transferrin 1 Selenium
- VEGF Vascular endothelial growth factor
- FGF fibroblast growth factor
- PDGF platelet-derived growth factor
- HUVEC human umbilical vein endothelial cells
- HAoEC t aortic endothelial cells
- O I R oxygen-induced retinopathy
- CNV choroidal neovascularization
- AMD age-related macular degeneration.
- ephrin B 2 and E ph B 4 are soluble proteins (hereinafter referred to as “5 ephrin: 82” and “sE pB4”, respectively) because of their availability; A protein that contains an outer domain but does not contain a cytoplasmic domain or a transmembrane domain).
- Mouse sephrin B 2 and s E ph B 4 were obtained from R & D Systems, Inc. (614 McKinley Place NE, Mmneapolis 55413, USA) (both in a form fused to the human F c domain). is there) . Proteins prepared as described in Example 5 below B, 2— HitoFc component protein was also used as ephrin B2.
- Example 1 Inhibition of growth and migration of EC stimulated by growth factors by ephrin B 2 and E ph B 4 on vascular endothelial cells stimulated by growth factors
- [ 3 H] thymidine incorporation—HA o EC and HUV EC DNA synthesis optoendothelial angiogenesis assays were performed.
- HA o EC and HU VEC in 5% CO, 95% air in endothelial cell growth medium (Clonetics Corp., San Diego, California, USA) on a dish coated with type 1 collagen (Iwalo, Japan)
- the cells were cultured at 37 ° C and maintained by changing the medium every 2-3 days. Cells from passage 4 to 5 were used in the experiment.
- Fig. 1A and Fig. 1B Treatment of human aortic endothelial cells (HAo EC) with VEGF, bFGF, or PDGF-BB increased DNA synthesis 3 to 10-fold compared to untreated controls.
- HAo EC human aortic endothelial cells
- FIGS. 1A and 1B show the effect of sephrin 2 on DNA synthesis induced by VEGF, bFGF, or PDGF-BB in HAo EC ( Figure 1A) and H UVEC ( Figure 1B), respectively. Symbols in the figure indicate C: control (untreated), B 2 ⁇ s ephrin B 2 treatment, and B 4: s E ph B 4 treatment, respectively.
- a vessel was defined as an elongated structure composed of one or more endothelial cells exceeding a length of 100 ⁇ .
- Five independent fields separated by the optical division of ⁇ were evaluated for each tool, and the average number of tubes per 20 mm field was measured. Cytotoxicity was assessed using Cell Proliferation Kit II purchased from ⁇ oehringer Mannheim.
- 7 days after treatment with either control (untreated), 's ephrin B 2 or s E ph B 4 or both s ephrin B 2 and s E ph B4, V The morphology of endothelial cells stimulated by EGF was observed. '
- Figure 1C shows V 'EGF-stimulated endothelium with control (untreated), treatment with either sephrin B2 or sEphB4, and treatment with both sephrin B2 and sEphB4 It is a photograph which shows the state of the 7th day of cell angiogenesis. VEGF-induced angiogenesis was reduced in the sephrin B2-treated group on day 7 compared to controls ( Figure 1C). Conversely, VEGF-induced angiogenesis was not affected by s Ep hB 4 treatment.
- ephrin B 2 was found to be able to inhibit EC DNA synthesis induced by various stimuli including VEGF, b FGF, and PDGF.
- the exact mechanism of ephrin B 2 is not clear, but the decrease in DNA synthesis was not caused by apoptosis because there was no significant apoptotic cell according to the assessment of cell toxicity. Seem. It is surprising that DNA synthesis is inhibited in both venous and arterial endothelial cells. This is because the receptor for Ephrin B 2 (E phB 4) is a marker for venous endothelial cells, but arterial endothelial cells are not known to have this receptor.
- ephrin B 2 is also VE Can inhibit EC angiogenesis induced by GF
- ERK (p 4 2/44) in endothelial cells stimulated with VEGF or b FGF on the mechanism by which ephrin B 2 inhibits the mitogenic response induced by VE F or b FGF against endothelial cells!
- the effect of ephrin B 2 on acidification was examined by Western analysis.
- EGM_DME EGM_DME
- M containing 3% FBS
- 10 ng / mL bFGF or 10 ng / mL VEGF Preparation of protein samples from endothelial cells and Western blotting were performed as follows. Whole cell lysates, cytosolic extracts, or nuclear extracts were isolated from endothelial cells. Western blotting was performed with and without immunoprecipitation.
- Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to a 2-trosenorelose membrane by electroporation. After blocking with skim ⁇ / c, blots at 4 ° C with phosphotyrosine or KDR, f-body against (s c-504) (purchased from Santa Cruz Biotechnology (Santa Cruz, California, USA)) ⁇ Incubated (1: 500). After washing, the membrane was incubated with a horseradish peroxidase-labeled secondary antibody (Bio-Rad, Richmond, California, USA) (1: 3000) for 1 hour at room temperature. Visualization was performed using an Amersham enhanced chemiluminescence (ECL) detection system according to the manufacturer's instructions.
- ECL Amersham enhanced chemiluminescence
- Figure 2A is an electrophoretogram showing the effect of ephrin B2 on ERK phosphorylation in HAo EC stimulated with VEGF or bFGF (p44 / p42) Total EK: pp 44 / pp 42: phosphorylated ERK).
- ERK phosphorylation was increased by treatment with 10 ⁇ g / mL VEGF or 25 ng / mL bFGF.
- Ephrin B 2 inhibited both £ 0-induced £ 11: Phosphorylation and bFGF-induced ERK phosphorylation.
- VEGF-induced ERK phosphorylation For example, 200 ng / mL 'sephrin B 2 inhibited VEGF-induced ERK phosphorylation by 70%.
- ephrin B 2 inhibited ERK phosphorylation in HA o EC by VEGF stimulation and bF GF stimulation.
- VEGF receptor 2 VEGF receptor 2
- ECs were left for 1 hour in the presence or absence of 50 ng Zm L of s'furin B 2 in EGM-DMEM (containing 3% FCS) (Nac al tesque, Japan). Furthermore, it was treated with 10 ng / mL VEGF for 5 minutes (the control was not treated).
- the receptor (KDR) was immunoprecipitated (IP) from the cell lysate and then plotted with an anti-phosphate tyrosine antibody (PY20).
- IP immunoprecipitated
- FIG. 2B is an electrophoretogram showing the effect of ephrin B 2 on VEGF receptor 2 (KDR) autophosphorylation in VEGF-stimulated HAo EC.
- KDR VEGF receptor 2
- FIG. 2B shows that ephrin B2 force has no significant effect on autophosphorylation of VEGF receptor 1-2 in VEGF-stimulated HAo EC.
- VEGF receptor 2 autophosphorylation was increased 14-fold at 10 ng / mL VEGF.
- sEphrin B 2 did not inhibit VE GF receptor 2 autophosphate.
- Ephrin B 2 force inhibits ERK phosphorylation induced by VEGF or bFGF in endothelial cells (arteries and veins). This effect may probably explain, at least in part, the activity of ephrin B2 to inhibit the proliferation of these cells induced by VEGF or bFGF. But Ephrin B 2 does not inhibit autophosphorylation of VEGF receptor 2. Thus, ephrin B2 is considered to not interfere with signaling between VEGF and VEGF receptor 2 as a mechanism for inhibiting VEGF function. (Example 3: Inhibition of angiogenesis induced by bFGF by simultaneous administration of ephrin B 2 in the mouse cornea)
- b FGF Basic FGF
- Kenyon, BM, et al. (1996) Ophthalmol. Vis. Sbi., 37 ⁇ , No. 8, pp. 1625-1632, essentially quantifying corneal pocket assembly and corneal angiogenesis in mice. This was done with some modifications. Briefly, 90 ng of human bF GF: 0.3 ⁇ L of Hydron pellets (IFN Sciences, New Brunswick, New Jersey, USA) was prepared and transplanted into the cornea of male BALB mice. sEphrin B 2 or s E ph B 4 (lOOngZ pellet) was added directly to the bF GF / Hydron solution. The pellet was placed 1.0 awake from the limbus. After transplantation, ofloxacin Z ophthalmic solution was applied to each eye.
- Hydron pellets IFN Sciences, New Brunswick, New Jersey, USA
- FIG. 3 shows the results of quantitative analysis of angiogenesis in the cornea of mice co-administered with bFGF and ephrinB2.
- the vertical axis in Fig. 3 is the value of the area of the area with angiogenesis.
- Example 4 Effect of Ephrin B 2 on Oxygen-induced Retinal Angiogenesis
- an oxygen-induced retinopathy (OIR) model was prepared as follows. Seven days after birth (P7) mice and their mothers were placed in a box with 75% hyperoxia for 5 days. On the 12th day after birth (P 12), 5 days after the hyperoxia, these mice were returned to normal 20% oxygen concentration and observed for subsequent retinal vascular responses. Mice treated with these treatments showed extensive development of retinal neovascularization. Retinal neovascularization occurred in 100% of animals by P 19. In P 19, the neovascular bundle is obvious, especially in the middle and peripheral parts, extending from the inner limiting membrane to the vitreous.
- mice were deeply anesthetized and 0.03 mL of 50 mg ZmL solution per lg body weight of 2 ⁇ 10 6 molecular weight fluorescein dextran (Sigma) was perfused into the left ventricle.
- the eyes were removed and fixed in 4% paraformaldehyde for at least 3 hours.
- the cornea and lens were then removed, the surrounding retina was dissected and flat mounted on a microscope slide for examination under a fluorescence microscope.
- Fig. 4 Fluorescence micrographs of flat-mounted fluorescein-dextran perfused retinas of control and sephrin-B treated model nore are shown in Fig. 4 (A: control mouth OIR model; B: s Ephrin B treatment model-). s Ephrin B treatment is clearly white from the center to the periphery of the flat-mounted retina (Fig. 4B). This indicates that there are normal blood vessels in the retina that can be perfused with fluorescein-dextran. In the ephrin-B treatment model, the presence of relatively normal blood vessels was observed in comparison with the OIR model (04A).
- FIG. 5 is a graph showing the area ratio of the non-perfused area of the sephrin B2 treatment model (01 scale + ephrin; 62) versus the control model (OIR).
- Fig. 6 is a SEM photograph showing the retinal surface of a P 1 7 newborn mouse in the control model (OIR) (A) and s ephrin B 2 treatment model (OI R + ephrin B 2) (B) (retina from the vitreous side). ) In the photograph of the control model in Fig.
- sEphrin B 2 goes out of the retina (in this example, it expands against the vitreous). It not only suppresses pathological angiogenesis but also enhances the formation of vascular networks and vascular maturation in the retina. obtain. Such an effect may be optimal for the treatment of diabetic retinopathy.
- Example 5 Antiangiogenic effect of human chemical furin B 2
- a fusion protein of ephrin B2 derived from a human DNA library and human Fc- was prepared, and its angiogenesis inhibitory effect was evaluated.
- the human ephrin B 2 cDNA fragment was fused to the 5 ′ end of cDNA encoding the Fc portion of human IgGl antibody.
- the distribution IJ of this human ephrin B 2 cDNA was based on US Pat. No. 6,303,769 or Mol Immunol. 1995 Nov; 32 ′ (16): 1197-205.
- Fc was cloned as follows.
- a human spleen cDNA library (100 ng) is used as a saddle, forward primer: GAA GAT CTC CCA AAT CTT GTG ACA AAA C TC (SEQ ID NO: 1) and reverse primer: GCG GCC GCT CAT TTA CCC GGA GA (sequence) No. 2) and PCR was performed using KODplus (T0Y0B0).
- the amplified DNA fragment of about 700 bp was purified, and the purified DNA fragment was subcloned into a Teasy vector (Promega) to confirm that it was human IgGlFc.
- Human ephrin B 2 was cloned as follows. Human placenta cDNA library (100 ng) as a saddle type, forward primer: GCG AAG CTT ACC ATG GC T GTG AGA AGG GAC (SEQ ID NO: 3) and reverse primer: GCG AGA TCT GGC CA PCR was performed using C TTC GGA ACC GAG GAT '(SEQ ID NO: 4) and KODplus (T0Y0B0). The amplified DNA fragment of about 680 bp was purified.
- the 5 'end of the cloned EFN-B2 DNA fragment was treated with HindIII, the 3' end with Bglll restriction enzyme, the 5 'end of the Fc DNA fragment with BglII, and the 3' end with Notl restriction enzyme. These fragments were subjected to three-party ligation using the mammalian expression vector pcDNA4-Myc-His A (Invitrogen) treated with Hindlll and Notl restriction enzymes and DNA Ligation kit ver. 2.1 (TAKARA). .
- the vector obtained by ligation was transformed into E. coli XL21.
- the plasmid was purified from the grown Escherichia coli colonies, and the nucleotide sequence was confirmed. As a result, it was human EFN-B2 (l-678bp) -Fc. '
- This plasmid was introduced into HEK293 cells and cultured under the following culture conditions.
- the medium used was DMEM (SIGMA) and 10% FBS (Biowest Fetal Bovine Serum) supplemented with an antibiotic (GIBC0 1% penicillin + 1% streptomycin). And cultured for 3 days at 37 ° C for at 5% C0 2 I Nkyubeta within one.
- Ephrin B2 stable expression strains were obtained by gene transfer by phosphate method and drug selection by Zeocin 250 g / mL (invivogen). When collecting the culture supernatant from the stable expression strain, it was cultured in GIT medium (Nippon Pharmaceutical Co., Ltd.).
- the expressed protein was purified from the ephrin B2_Fc stable expression strain as follows.
- FIG. 7 shows the ratio (%) with respect to the case without bF GF and ephrin B 2 treatment (the leftmost column in the figure).
- CNV laser-induced choroidal neovascularization
- CNV choroidal neovascularization
- Experimental C NV was induced by photocoagulation using a multicolor laser (Novus Omni Laser; Lumenis, Santa Clara, Calif) at the posterior pole of the fundus of the monkey eye.
- the spot size was 100 / zm in diameter and the irradiation time was 0.1 seconds.
- the output at the corneal surface was 700 mW.
- the intravitreal administration of the human ephrin B 2-human Fc synthetic protein prepared in Example 5 was performed twice immediately after laser irradiation and five days after irradiation. Efre in the vitreous A PBS solution adjusted to have B2 concentrations of lng / mL, 10 ng / raL, and lOOng / mL was injected into the eye from the flat portion of the ciliary body using a 27G needle in an amount of 0.1 lmL each. As a negative control, 0.1 ml of PBS was injected. As a positive control, lOng / mL and lOOng / mL of the above mouse ephrin B2-human Fc chimeric protein were used.
- a fluoroscopic angiography was performed to evaluate choroidal neovascularization.
- 0. lmL / kg of 5% fluorescein Na was administered intravenously, and fluorescence fundus photography was performed with a fundus force mela (TRC-50EX, Topcon Co., Ltd.).
- Increased permeability of choroidal neovascularization was evaluated for fluorescent fundus photographs 5 to 6 minutes after the start of injection.
- the photographic evaluation was performed by a skilled ophthalmologist. Except for the three eyes that could not be evaluated due to the opacity of the intermediate translucent body, lesions with markedly increased permeability of the fluorescent dye were determined to be active for each laser spot.
- Fig. 8 is a fluorescence photograph of the fundus oculi subjected to the following processes.
- Fig. 8A shows the results of treatment with 10 ng / mL of hetefrin B 2
- Fig. 8 B shows the results of negative control '(P B S treatment)
- Fig. 8 C shows the results of treatment with lOng / mL of mouse ephrin B 2.
- human ephrin B 2 -human Fc synthetic protein inhibits neovascularization in a laser-induced CNV model ⁇ .
- concentration in the vitreous was effective at 10 ng / mL.
- Ephrin B 2 is expressed in the pigment epithelium that has migrated in the laser model (data not shown). Therefore, it was speculated that vascularization of new blood vessels would be stopped by the expression of ephrin B 2 force S and pigment epithelium.
- the results of this example demonstrated the effect of ephrin B 2 on inhibiting neovascularization.
- compositions and methods of the present invention are useful for the treatment of diseases or disorders associated with angiogenesis or angiogenesis.
- the composition and method of the present invention can suppress pathological angiogenesis and angiogenesis outside the retina without suppressing physiological blood flow in the retina.
- the composition method of the present invention provides AMD and diabetic retinas as compared to current therapies as proposed by injection of PDT and various anti-angiogenic agents (eg, anti-VEGF agents). It can be used with particular advantage in the treatment of ophthalmic diseases associated with angiogenesis or angiogenesis such as infectious diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2006300222A AU2006300222A1 (en) | 2005-10-05 | 2006-10-05 | Method of inhibiting angiogenesis by using ephrin B2 |
US12/088,634 US20090270315A1 (en) | 2005-10-05 | 2006-10-05 | Method of inhibiting angiogenesis by using ephrin b2 |
EP06811711A EP1932534A1 (en) | 2005-10-05 | 2006-10-05 | Method of inhibiting angiogenesis by using ephrin b2 |
JP2007539989A JPWO2007043629A1 (ja) | 2005-10-05 | 2006-10-05 | エフリンb2を用いる血管新生の抑制方法 |
CA002623563A CA2623563A1 (en) | 2005-10-05 | 2006-10-05 | Method of inhibiting angiogenesis by using ephrin b2 |
IL190395A IL190395A0 (en) | 2005-10-05 | 2008-03-24 | Methods for suppressing neovascularization using ephrinb2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-292406 | 2005-10-05 | ||
JP2005292406 | 2005-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007043629A1 true WO2007043629A1 (ja) | 2007-04-19 |
Family
ID=37942853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/320423 WO2007043629A1 (ja) | 2005-10-05 | 2006-10-05 | エフリンb2を用いる血管新生の抑制方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090270315A1 (ja) |
EP (1) | EP1932534A1 (ja) |
JP (1) | JPWO2007043629A1 (ja) |
KR (1) | KR20080066916A (ja) |
CN (1) | CN101257915A (ja) |
AU (1) | AU2006300222A1 (ja) |
CA (1) | CA2623563A1 (ja) |
IL (1) | IL190395A0 (ja) |
WO (1) | WO2007043629A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017141306A (ja) * | 2009-08-24 | 2017-08-17 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 眼疾患を予防または治療するための方法および組成物 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012112434A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using retargeted endopeptidases |
CN104694477B (zh) * | 2015-03-03 | 2018-04-17 | 西安交通大学 | 一种EphrinB2高表达的重组HEK293细胞及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026827A1 (en) * | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
WO2006006079A2 (en) * | 2004-04-05 | 2006-01-19 | Aqumen Biopharmaceuticals K.K. | Methods for suppressing neovascularization using ephrinb2 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011384A1 (en) * | 1992-11-13 | 1994-05-26 | Immunex Corporation | Novel cytokine designated elk ligand |
US6303769B1 (en) * | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
US5864020A (en) * | 1994-07-20 | 1999-01-26 | Genentech, Inc. | HTK ligand |
US6864227B1 (en) * | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
JP2002530350A (ja) * | 1998-11-20 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 血管障害を処置するためのEphレセプターのアンタゴニストおよびアゴニストについての使用 |
EP1337276B1 (en) * | 2000-11-20 | 2007-03-14 | California Institute Of Technology | Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
US20040110150A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of Ephrin-B2 expression |
-
2006
- 2006-10-05 EP EP06811711A patent/EP1932534A1/en not_active Withdrawn
- 2006-10-05 KR KR1020087005246A patent/KR20080066916A/ko not_active Application Discontinuation
- 2006-10-05 WO PCT/JP2006/320423 patent/WO2007043629A1/ja active Application Filing
- 2006-10-05 AU AU2006300222A patent/AU2006300222A1/en not_active Abandoned
- 2006-10-05 US US12/088,634 patent/US20090270315A1/en not_active Abandoned
- 2006-10-05 JP JP2007539989A patent/JPWO2007043629A1/ja not_active Withdrawn
- 2006-10-05 CA CA002623563A patent/CA2623563A1/en not_active Abandoned
- 2006-10-05 CN CNA2006800324057A patent/CN101257915A/zh active Pending
-
2008
- 2008-03-24 IL IL190395A patent/IL190395A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026827A1 (en) * | 2000-09-29 | 2002-04-04 | Novartis Ag | Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules |
WO2006006079A2 (en) * | 2004-04-05 | 2006-01-19 | Aqumen Biopharmaceuticals K.K. | Methods for suppressing neovascularization using ephrinb2 |
Non-Patent Citations (5)
Title |
---|
HATA Y. ET AL.: "INHIBITORY EFFECTS AND MECHANISMS ON THE PROLIFERATION OF VASCULAR ENDOTHELIAL CELLS BY EPHIRIN - B2", ARVO JOURNAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2003, 2003, pages ABSTR. NO. 2883, XP002996326 * |
KIM I. ET AL.: "EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin-1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells", FASEB JOURNAL, vol. 16, no. 9, 2002, pages 1126 - 1128, XP002996328 * |
MIURA S. ET AL.: "Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470", CANCER LETTERS, vol. 203, no. 1, January 2004 (2004-01-01), pages 45 - 50, XP002996327 * |
PATTERSON C. ET AL.: "Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells", JOURNAL OF CLINICAL INVESTIGATION, vol. 98, no. 2, 1996, pages 490 - 496, XP000604153 * |
ZAMORA D.O. ET AL.: "Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 46, no. 6, June 2005 (2005-06-01), pages 2175 - 2182, XP003010452 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017141306A (ja) * | 2009-08-24 | 2017-08-17 | ステルス ペプチドズ インターナショナル インコーポレイテッド | 眼疾患を予防または治療するための方法および組成物 |
US10188692B2 (en) | 2009-08-24 | 2019-01-29 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating ophthalmic conditions |
US11612633B2 (en) | 2009-08-24 | 2023-03-28 | Stealth Biotherapeutics Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
US11944662B2 (en) | 2009-08-24 | 2024-04-02 | Stealth Biotherapeutics Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
Also Published As
Publication number | Publication date |
---|---|
JPWO2007043629A1 (ja) | 2009-04-16 |
CN101257915A (zh) | 2008-09-03 |
KR20080066916A (ko) | 2008-07-17 |
EP1932534A1 (en) | 2008-06-18 |
AU2006300222A1 (en) | 2007-04-19 |
IL190395A0 (en) | 2008-11-03 |
CA2623563A1 (en) | 2007-04-19 |
US20090270315A1 (en) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7306799B2 (en) | Use of VEGF inhibitors for treatment of eye disorders | |
Khalin et al. | Targeted delivery of brain-derived neurotrophic factor for the treatment of blindness and deafness | |
JP5529536B2 (ja) | 虚血性障害又は血管不全の治療におけるDll4アンタゴニストの使用 | |
Oshima et al. | Angiopoietin‐2 enhances retinal vessel sensitivity to vascular endothelial growth factor | |
CA2621047A1 (en) | Method of treating eye injury with local administration of a vegf inhibitor | |
IL138033A (en) | Use of fgf - 5 polypeptides for preparing medicaments for preventing the death of retinal neurons and treating ocular diseases | |
Kano et al. | Protective effect against ischemia and light damage of iris pigment epithelial cells transfected with the BDNF gene | |
JP2006089489A (ja) | 網膜疾患用医薬 | |
Usui et al. | Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor | |
JP2003522160A (ja) | 眼関連疾患の治療のための遺伝子治療 | |
WO2007043629A1 (ja) | エフリンb2を用いる血管新生の抑制方法 | |
Irani et al. | An Anti–VEGF-B Antibody Fragment Induces Regression of Pre-Existing Blood Vessels in the Rat Cornea | |
Davies et al. | Increased retinal neovascularization in Fas ligand–deficient mice | |
US7300654B2 (en) | Method of treating corneal transplant rejection in high risk keratoplasty patients | |
JP2019530675A (ja) | mTOR阻害剤を含有する黄斑変性治療用薬学組成物 | |
JP3983271B1 (ja) | エフリンb2を用いた新生血管抑制方法 | |
WO1999024056A1 (en) | Regulation of ocular angiogenesis | |
WO2011066182A2 (en) | Socs3 inhibition promotes cns neuron regeneration | |
Unsoeld et al. | Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice | |
JPH10273450A (ja) | 眼内血管新生性疾患治療薬 | |
US7476654B2 (en) | Method for modulating, regulating and/or stabilizing angiogenesis | |
MX2008004518A (en) | Method of inhibiting angiogenesis by using ephrin b2 | |
US20160331807A1 (en) | Therapeutic use of vegfr-3 ligands | |
Lin | Retinal Growth Hormone: An Autocrine/paracrine in the Developing Chick Retina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680032405.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2007539989 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087005246 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 190395 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2623563 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006300222 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1532/CHENP/2008 Country of ref document: IN Ref document number: 2006811711 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/004518 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006300222 Country of ref document: AU Date of ref document: 20061005 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12088634 Country of ref document: US |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0617543 Country of ref document: BR Free format text: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER O ART. 9.2 DO ATO NORMATIVO 128 DE 05/03/97. EMBORA A DOCUMENTACAO TENHA SIDO APRESENTADA TRADUZIDA DENTRO DO PRAZO DE 60 DIAS APOS A PETICAO DE ENTRADA NA FASE NACIONAL, NAO FOI APRESENTADO QUADRO REIVINDICATORIO NA PETICAO INICIAL NEM HOUVE PEDIDO DE DESARQUIVAMENTO. |